代谢功能障碍相关脂肪性肝病失代偿期肝硬化再代偿研究
本研究评估了失代偿期MASLD和MetALD肝硬化患者再代偿(Baveno VII标准)的发生率、预测因素及干预后结局。344例患者中64例(18.6%)实现再代偿,中位时间15个月;体重减轻≥10%、戒酒和血糖控制与再代偿独立相关,持续饮酒与死亡率相关。
要点
- 失代偿期MASLD/MetALD肝硬化再代偿率为18.6%,中位时间15个月。
- 体重减轻≥10%、戒酒、血糖控制和无大食管静脉曲张与再代偿独立相关。
- MetALD病因、高MELD-Na、未再代偿和持续饮酒与死亡率相关。
核心结论
- PEth提高了酒精暴露的确定和MASLD与MetALD的表型分型。
- 体重减轻≥10%、实现血糖控制和无大食管静脉曲张与再代偿独立相关。
- 18.6%的失代偿期MASLD/MetALD肝硬化患者实现再代偿。
研究设计与样本
- 队列研究,纳入2019年10月至2025年3月间344例失代偿期MASLD/MetALD肝硬化患者(平均MELD-Na 14.7±3.6;MASLD 158例,MetALD 186例)。
- 评估再代偿(Baveno VII标准)的发生率和预测因素,以及可干预措施(戒酒、干体重减轻、心脏代谢风险管理)后的结局。
主要发现
- 64例(18.6%)实现再代偿,MASLD 17.7%,MetALD 19.4%,中位随访3.9年(IQR 2.8-4)期间再代偿中位时间15个月(IQR 14.5-15.5)。
- 基线PEth在MASLD中阴性,在MetALD患者中69.4%阳性(p=0.001)。
- 61例(17.7%)死亡,11例(3.2%)接受肝移植,5例(1.5%)发生肝细胞癌。
- MASLD死亡率低于MetALD(12.0% vs. 22.6%;p=0.011)。
关键数值与推荐
- 竞争风险回归(校正基线MELD-Na)显示:无大食管静脉曲张(sHR 1.97,95% CI 1.22-3.99;p=0.021)、体重减轻≥10%(sHR 7.42,95% CI 3.15-17.47;p<0.001)、戒酒(sHR 1.87,95% CI 1.29-3.32;p=0.003)和血糖控制(sHR 1.43,95% CI 1.03-2.79;p=0.038)与再代偿相关。
- 较高MELD-Na(sHR 1.13,95% CI 1.06-1.2;p<0.001)、MetALD病因(sHR 1.87,95% CI 1.09-3.22;p=0.023)、未再代偿(p<0.001)和持续饮酒(sHR 5.3,95% CI 2.85-9.74;p<0.001)与死亡率相关。
临床怎么用
- 对失代偿期MASLD/MetALD肝硬化患者,应积极管理可干预因素:促进体重减轻≥10%、实现血糖控制、戒酒。
- 使用PEth有助于准确评估酒精暴露,区分MASLD与MetALD。
- 基线无大食管静脉曲张、较低MELD-Na提示再代偿可能性更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Recompensation of decompensated metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatotic liver disease with alcohol consumption (MetALD) cirrhosis remains unknown. APPROACH: We assessed rates and predictors of recompensation (Baveno VII criteria) and outcomes after modifiable interventions, including alcohol abstinence, dry-weight loss, and cardiometabolic risk factor management, in a cohort of patients with decompensated MASLD/MetALD cirrhosis between October 2019 and March 2025. RESULTS: Among 344 patients with steatotic liver disease-related cirrhosis (mean MELD-Na 14.7±3.6; MASLD-158, MetALD-186), 64(18.6%) achieved recompensation; MASLD (17.7%) and MetALD (19.4%), at a median of 15 months(IQR: 14.5-15.5) over 3.9 years (IQR: 2.8-4) follow-up. Baseline phosphatidylethanol (PEth) was negative in MASLD but positive in 69.4% of MetALD patients ( p =0.001). In all, 61 patients (17.7%) died, 11 (3.2%) underwent liver transplantation, and 5 (1.5%) developed hepatocellular carcinoma. Mortality was lower in MASLD than in MetALD (12.0% vs. 22.6%; p =0.011). In competing-risk regression adjusted for baseline MELD-Na, absence of large esophageal varices (sHR 1.97, 95% CI: 1.22-3.99; p =0.021), weight loss ≥10% (sHR 7.42, 95% CI: 3.15-17.47; p <0.001), alcohol abstinence (sHR 1.87, 95% CI: 1.29-3.32; p =0.003), and glycemic control (sHR 1.43, 95% CI: 1.03-2.79; p =0.038) were associated with recompensation. Higher MELD-Na (sHR 1.13, 95% CI: 1.06-1.2; p <0.001), MetALD etiology (sHR 1.87, 95% CI: 1.09-3.22; p =0.023), lack of recompensation ( p <0.001), and ongoing alcohol consumption (sHR 5.3, 95% CI: 2.85-9.74; p <0.001) were associated with mortality. CONCLUSIONS: PEth improved the ascertainment of alcohol exposure and phenotyping of MASLD and MetALD. Weight loss ≥10%, achievement of glycemic control, and absence of large varices were independently associated with recompensation, which occurred in 18.6% of patients with decompensated MASLD/MetALD cirrhosis.
引用
- Premkumar M, Sandhu A, Sharma P, et al. Recompensation of decompensated cirrhosis in a spectrum of metabolic dysfunction-related steatotic liver disease, with PEth-corroborated alcohol abstinence and modification of cardiometabolic risk factors. Hepatology. 2026. PMID: 42467948. doi:10.1097/HEP.0000000000001822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。